Seagen is a global biotechnology company that discovers, develops, manufactures, and commercializes targeted cancer therapeutics, with antibody-drug conjugates (ADCs) at its core. The company has a pipeline of therapies at various stages of testing and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary ADCs and immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors. For more information, visit www.seagen.com.